Boundless Bio Quote - BOLD

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

3.02

Bid

2.92

Offer

3.15

Volume

46,253

2.92 Day's Range 3.149

2.85 52 Week Range 59.97

Market Cap

67.209M

Previous Close

2.93

Open

2.95

Last Trade

2.92

Last Trade Time

Financial Volume

US$ 139,451

VWAP

3.015

Average Volume (3m)

66,737

Shares Outstanding

22,254,537

Dividend Yield

PE Ratio

-1.36

Earnings Per Share (EPS)

-2.22

Revenue

Net Profit

-49.43M

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.boundlessbio.com

Headquarters

Wilmington, Delaware, USA

Founded

Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was US$2.93. Over the last year, Boundless Bio shares have traded in a share price range of US$ 2.85 to US$ 59.97.

Boundless Bio currently has 22,254,537 shares in issue. The market capitalisation of Boundless Bio is US$65.21 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.36.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.17	-5.32915360502	3.19	3.39	2.9	33623	3.0465494	CS
4	-0.26	-7.92682926829	3.28	4.72	2.9	65652	3.62650505	CS
12	-0.9687	-24.2861082558	3.9887	4.72	2.85	66737	3.51509375	CS
26	-8.84	-74.5362563238	11.86	12.6484	2.85	92737	6.38204727	CS
52	-56.95	-94.964148741	59.97	59.97	2.85	59870	7.89860033	CS
156	-56.95	-94.964148741	59.97	59.97	2.85	19983	7.89860033	CS
260	-25.2	-89.2983699504	28.22	60	2.85	91722	47.54564847	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CAMPCAMP4 Therapeutics Corporation	10.75 (2,587.50%)	378.47k
TWGTop Wealth Group Holding Ltd	US$ 7.14 (233.64%)	149.99M
NIVFNewGenIvf Group Ltd	US$ 0.98 (63.42%)	57.16M
ATIFATIF Holdings Ltd	US$ 1.235 (58.33%)	3.85M
VERBVerb Technology Company Inc	US$ 7.91 (51.82%)	15.55M
BYUBAIYU Holdings Inc	US$ 0.299 (-35.28%)	11.11M
TURBTurbo Energy SA	US$ 2.1511 (-29.01%)	3.2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF	US$ 7.898 (-23.62%)	993.33k
VEEAVeea Inc	US$ 3.27 (-23.24%)	284.95k
INHDInno Holdings Inc	US$ 3.74 (-22.41%)	257.75k
JTAIJet AI Inc	US$ 0.1009 (23.50%)	340.09M
CDTConduit Pharmaceuticals Inc	US$ 0.116 (13.28%)	270.97M
NVDANVIDIA Corporation	US$ 134.80 (-0.01%)	170.27M
LUXHLuxUrban Hotels Inc	US$ 0.0532 (5.35%)	165.94M
TWGTop Wealth Group Holding Ltd	US$ 7.14 (233.64%)	154.23M